PATENT CLAIM ANALYSIS

Application Number: 15972655
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "472000"]

Abstract:
A pharmaceutical composition comprises at least one integrase inhibitor or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug and at least one antiretroviral or anti-HIV agent or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug.

Claim (Index 5):
The pharmaceutical composition according to  claim 1 , wherein the at least one antiretroviral or anti-HIV agent is selected from tenofovir, zidovudine, didanosine, stavudine, lamivudine, abacavir, adefovir, lobucavir, entecavir, apricitabine, emtricitabine, zalcitabine, dexelvucitabine, alovudine, amdoxovir, elvucitabine, stampidine, Iodenosine, adefovir, nevirapine, rilpivirine, delaviridine, efavirenz, etravirine, emivirine saquinavir, ritonavir, nelfinavir amprenavir, lopinavir, indinavir, nelfinavir, atazanavir, lasinavir, palinavir, tipranavir, fosamprenavir, darunavir or any combination thereof.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 93.0
- Lexical Diversity: 2.28571
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14429651', '14744915', '15624166', '15280801', '13004533']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7596058712340805
- 35 USC 102 Novelty (BERT): 0.5682123623943129
- Combined Prediction Score: 0.7404665203501037
- Mean Citation Score: 313.305146
- Max Citation Score: 475.60028
- Similarity Product: 351.9959468096614

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test